Prospective, Observational Study on the Carotid Intima-media Thickness in Patients Undergoing Thyroid Surgery

NCT ID: NCT05774535

Last Updated: 2025-10-02

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Study Classification

OBSERVATIONAL

Study Start Date

2022-09-05

Study Completion Date

2024-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The evaluation of carotid intima-media thickness (cIMT) has become a possible predictor of the future risk of cardiovascular diseases (CVD). Evidence to date shows that cIMT augmentation is correlated with the extent of atherosclerosis in the coronary arteries and with other risk factors for CVD. More recently, several studies have evaluated the association of cIMT with stroke, to determine whether this measure can also predict future cardiovascular events.

Although the published evidence is scarce and fragmentary, the cIMT retains an increasingly interesting role as a marker of atherosclerotic pathology.

The purpose of the study is to analyze cIMT in patients undergoing thyroidectomy to evaluate a possible correlation between the cIMT variation after the procedure and the cause of the thyroid disease, the levels of thyroid hormones, and the lipid or other markers of atherosclerosis levels.

The primary endpoint will be the variation of the measure of the cIMT before and after surgery.

Secondary endpoints will be:

* major cardiovascular adverse events (death, major stroke, minor stroke, transient ischemic attack) in the short-term period (≤30 days after the procedure);
* major cardiovascular adverse events (death, major stroke, minor stroke, transient ischemic attack) in the long-term period (\>30 days after the procedure);
* the technical success of the procedure;
* the rate of postoperative complications. To date, there are no data that differentiate patients based on the causes of thyroid disease. The results of the present study will allow for correlating the variation of the cIMT to the causes of thyroid disease, the levels of thyroid hormones, and the levels of lipid and other markers of atherosclerosis.

Results from the present study may provide insights into possible areas of quality improvement. It may also influence the economic impact associated with carotid revascularization techniques, in terms of hospital charges and discharges to skilled nursing and rehabilitation facilities.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Plummer Disease Multinodular Goiter Graves Disease Hyperthyroidism Euthyroid Goiter Thyroid Cancer Basedow Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Experimental

Patients who will undergo thyroidectomy

Experimental

Intervention Type OTHER

Patients will undergo thyroidectomy according to the guidelines American Thyroid Association (ATA), Randolph.

The following assessments will be performed within 10 days before the thyroidectomy procedure:

* informed consent;
* personal data and medical records;
* registration of medical therapy and post-procedural pharmacological protocol
* surgical check;
* supra-aortic trunks EchocolorDoppler;
* pre-procedural blood sampling.

The following assessments will be performed after 30 days, 6 months and 12 months from the thyroidectomy procedure:

* surgical checks;
* registration of drug therapy;
* recording of all adverse events that occurred during hospitalization
* supra-aortic trunks EchocolorDoppler and cIMT measurement;
* blood sampling.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Experimental

Patients will undergo thyroidectomy according to the guidelines American Thyroid Association (ATA), Randolph.

The following assessments will be performed within 10 days before the thyroidectomy procedure:

* informed consent;
* personal data and medical records;
* registration of medical therapy and post-procedural pharmacological protocol
* surgical check;
* supra-aortic trunks EchocolorDoppler;
* pre-procedural blood sampling.

The following assessments will be performed after 30 days, 6 months and 12 months from the thyroidectomy procedure:

* surgical checks;
* registration of drug therapy;
* recording of all adverse events that occurred during hospitalization
* supra-aortic trunks EchocolorDoppler and cIMT measurement;
* blood sampling.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients undergoing thyroidectomy according to the American Thyroid Association (ATA), International neural monitoring study group guideline (INMSG), Italian Society of Endocrine Surgery (SIUEC);
* subjects who have read and signed the informed consent;
* subjects who undertake to undergo the instrumental examinations and visits necessary for the study during the follow-up;
* \>18 years of age.

Exclusion Criteria

* occlusion or stenosis of at least one carotid artery, with plaque \> 30%;
* exposure to ionizing radiation;
* previous neck, carotid (endarterectomy or stenting) and/or thyroid surgery;
* clinical conditions that preclude proper follow-up;
* HIV, dialysis therapy and all clinical conditions with increased cIMT;
* uncontrolled dyslipidemia;
* pregnant and breastfeeding women;
* terminal patients.
Minimum Eligible Age

18 Years

Maximum Eligible Age

100 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Istituto Auxologico Italiano

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Istituto Auxologico Italiano , IRCCS

Milan, , Italy

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Italy

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

34C211

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Studies on Tumors of the Thyroid
NCT00001160 RECRUITING